Use of amyloid PET across the spectrum of Alzheimer's disease: clinical utility and associated ethical issues (Q38219529)

31 August 2017

Use of amyloid PET across the spectrum of Alzheimer's disease: clinical utility and associated ethical issues (English)

1 reference

31 August 2017

0 references

0 references

1 reference

4

Pedro Rosa-Neto

1 reference

31 August 2017

Antoine Leuzy

1

1 reference

31 August 2017

Eduardo Rigon Zimmer

series ordinal

2

1 reference

31 August 2017

Kerstin Heurling

series ordinal

3

1 reference

31 August 2017

Serge Gauthier

series ordinal

5

1 reference

31 August 2017

11 June 2014

1 reference

31 August 2017

1 reference

31 August 2017

21

1 reference

31 August 2017

3

1 reference

31 August 2017

143-148

1 reference

Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association

31 August 2017

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Clinical applications of neuroimaging in patients with Alzheimer's disease: a review from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Amyloid imaging with PET in early Alzheimer disease diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

21 January 2018

Brain amyloid imaging

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Clinical validation of 18F-AZD4694, an amyloid-β-specific PET radioligand.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Mild cognitive impairment: clinical characterization and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Imaging beta-amyloid burden in aging and dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

The progression of pathology in longitudinally followed patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Frequent amyloid deposition without significant cognitive impairment among the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Neuropathology of older persons without cognitive impairment from two community-based studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Clinical and biomarker changes in dominantly inherited Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Using AD biomarker research results for clinical care: a survey of ADNI investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Disclosure of individual genetic data to research participants: the debate reconsidered

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Dementia: Disclosure of results to participants in dementia research

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Communicating the results of clinical research to participants: attitudes, practices, and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Psychological consequences of predictive genetic testing: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Impact of presymptomatic genetic testing for hereditary ataxia and neuromuscular disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Impact of DNA testing for early-onset familial Alzheimer disease and frontotemporal dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Disclosure of amyloid imaging results to research participants: has the time come?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

The Impact of Experience with a Family Member with Alzheimer's Disease on Views about the Disease across Five Countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Amyloid imaging: liberal or conservative? Let the data decide.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Amyloid imaging: coming to a PET scanner near you.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

Amyloid imaging: the court of public opinion.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.926267

10.3109/13506129.2014.926267

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference